共 50 条
- [21] FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Migliorino, RitaLandi, LorenzaGaletta, DomenicoSoregaroli, DanielaRicciardi, SerenaMinuti, GabrieleMontrone, MicheleMarech, IlariaMorabito, AlessandroBerardi, RossanaNovello, SilviaRocco, DaniloPilotto, SaraZanelli, FrancescaBengala, CarmeloDelmonte, AngeloAieta, MicheleCortinovis, Diego LuigiCappuzzo, Federico
- [22] Preliminary results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A single-arm, multicenter phase II clinical trialJOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 444 - 444Jia, Yong-XuChang, ZhiweiZhong, Ya-LiCui, DonghaiHan, Hui-QiongGao, Ya-PingHe, JianLiu, Xiao-LeiYan, JieQin, Yanru
- [24] Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Verschraegen, Claire F.Chen, FranklinSpigel, David R.Iannotti, NicholasMcClay, Edward FrancisRedfern, Charles H.Bennouna, JaafarTaylor, Matthew H.Kaufman, HowardKelly, KarenBajars, Marcisvon Heydebreck, AnjaCuillerot, Jean-MarieJerusalem, Guy Heinrich Maria
- [25] Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma HCRN GU17-295JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)Adra, NabilHauke, Ralph J.Kaimakliotis, Hristos Z.Gulati, ShuchiHashemi, NedaPili, Roberto
- [26] SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, as first-line therapy for PD-L1+advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I studyANNALS OF ONCOLOGY, 2021, 32 : S995 - S995Feng, J.Chen, J.Li, K.Li, X.Min, X.Li, B.Lin, L.Fang, Y.Sun, Y.Zhu, B.Wang, Q.Wang, L.Zou, J.Liu, P.
- [27] Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)EUROPEAN JOURNAL OF CANCER, 2015, 51 : S717 - S718Besse, B.Johnson, M.Jaenne, P. A.Garassino, M.Eberhardt, W. E. E.Peters, S.Toh, C. K.Kurata, T.Li, Z.Kowanetz, M.Mocci, S.Sandler, A.Rizvi, N. A.
- [28] Comparative analysis of first-line treatment in NSCLC including unresectable stage III (IIIB/IIIC) and stage IV with low PD-L1 expression: Clinical trial eligible versus ineligible patientsLUNG CANCER, 2025, 200Hata, TaeYamada, TadaakiGoto, YasuhiroAmano, AkihikoNegi, YoshikiWatanabe, SatoshiFuruya, NaokiOba, TomohiroIkoma, TatsukiNakao, AkiraTanimura, KeikoTaniguchi, HirokazuYoshimura, AkihiroFukui, TomoyaMurata, DaikiKaira, KyoichiShiotsu, ShinsukeHibino, MakotoOkada, AsukaChihara, YusukeKawachi, HayatoKijima, TakashiTakayama, Koichi
- [29] Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line ChemoimmunotherapyCURRENT ONCOLOGY, 2024, 31 (09) : 4955 - 4967Putzu, CarloSerra, RiccardoCampus, RacheleFadda, Giovanni MariaSini, ClaudioMarongiu, AndreaGinesu, Giorgio CarloFois, Alessandro GiuseppePalmieri, GiuseppeZinellu, AngeloCossu, AntonioPaliogiannis, Panagiotis
- [30] Surufatinib plus toripalimab for first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 positive expression: A multicenter, single-arm phase 2 studyCANCER RESEARCH, 2023, 83 (08)Cheng, YingShen, LinChen, ZhendongYe, FengYu, XianjunZhang, XingJi, DongmeiLiu, BaoruiSong, LijieWu, ChunjiaoLu, MingChen, WeiWu, JingxunGao, HeliWeng, DeshengShen, WeinaLi, RutianYang, MinjieZhou, JinghongShi, HaiyanTan, PanfengFan, SonghuaShi, MichaelSu, Weiguo